Progress and challenges in the synthesis of sequence controlled polysaccharides

• Giulio Fittolani,
• Theodore Tyrikos-Ergas,
• Denisa Vargová,
• Manishkumar A. Chaube and
• Martina Delbianco

Beilstein J. Org. Chem. 2021, 17, 1981–2025, doi:10.3762/bjoc.17.129

• substitution. A collection of linear β(1–4)-ᴅ-xylan chains and with α(1–3)-ʟ-arabinofuranosyl branches was quickly assembled to identify the binding epitopes of monoclonal antibodies. These oligomers, together with other well-defined analogues obtained by chemoenzymatic synthesis, were converted to the

Synthesis and physicochemical evaluation of fluorinated lipopeptide precursors of ligands for microbubble targeting

• Masayori Hagimori,
• Estefanía E. Mendoza-Ortega and
• Marie Pierre Krafft

Beilstein J. Org. Chem. 2021, 17, 511–518, doi:10.3762/bjoc.17.45

• , which involves the use of targeting ligands, such as monoclonal antibodies, antibody fragments, proteins, peptides, and other small molecules, including vitamins and carbohydrates [7][8]. The targeting ligands are coupled to the surface of the carrier to selectively target tumor cells that overexpress a

The B & B approach: Ball-milling conjugation of dextran with phenylboronic acid (PBA)-functionalized BODIPY

• Patrizia Andreozzi,
• Lorenza Tamberi,
• Elisamaria Tasca,
• Gina Elena Giacomazzo,
• Marta Martinez,
• Mirko Severi,
• Marco Marradi,
• Stefano Cicchi,
• Sergio Moya,
• Giacomo Biagiotti and
• Barbara Richichi

Beilstein J. Org. Chem. 2020, 16, 2272–2281, doi:10.3762/bjoc.16.188

• regard, we recently reported on the straightforward synthesis of probe 1 (Figure 1) where a phenylboronic acid (PBA) moiety was introduced at the meso position of a BODIPY core. We demonstrated the compound’s ability to bind the oligosaccharide chain of the Fc domain of monoclonal antibodies, through the

Clustering and curation of electropherograms: an efficient method for analyzing large cohorts of capillary electrophoresis glycomic profiles for bioprocessing operations

• Ian Walsh,
• Matthew S. F. Choo,
• Sim Lyn Chiin,
• Amelia Mak,
• Shi Jie Tay,
• Pauline M. Rudd,
• Yang Yuansheng,
• Andre Choo,
• Ho Ying Swan and
• Terry Nguyen-Khuong

Beilstein J. Org. Chem. 2020, 16, 2087–2099, doi:10.3762/bjoc.16.176

• ; electropherogram; glycosylation; monoclonal antibodies; peak picking; process development; Introduction Glycosylation is important for the efficacy and function of a majority of the most dominant biologic drugs currently on the global market. In the case of antibody-based biotherapeutics, the absence of

Automated glycan assembly of arabinomannan oligosaccharides from Mycobacterium tuberculosis

• Alonso Pardo-Vargas,
• Priya Bharate,
• Martina Delbianco and
• Peter H. Seeberger

Beilstein J. Org. Chem. 2019, 15, 2936–2940, doi:10.3762/bjoc.15.288

• lipoarabinomannan (LAM) analogs in urine samples using the Alere lateral flow urine (LF)-LAM assay [13]. However, the low sensitivity of the Alere assay limits its scope. Glycan array screening of more than 100 monoclonal antibodies against more than 60 synthetic glycans related to the mycobacterial cell wall

A chemically contiguous hapten approach for a heroin–fentanyl vaccine

• Yoshihiro Natori,
• Candy S. Hwang,
• Lucy Lin,
• Lauren C. Smith,
• Bin Zhou and
• Kim D. Janda

Beilstein J. Org. Chem. 2019, 15, 1020–1031, doi:10.3762/bjoc.15.100

• States has necessitated the development of new strategies to treat addiction. Monoclonal antibodies and antidrug vaccines provide a tool that both aids addiction management and reduces the potential for overdose. Dual drug vaccines formulated by successive conjugation or by mixture have certain drawbacks

• not limited to, new non-addictive opioid drugs, innovative treatments to prevent relapse, and preventing and/or reversing overdose. Monoclonal antibodies and antidrug vaccines are immunopharmacological treatments that address two of these highlighted needs: addiction management and a potential for

Glyco-gold nanoparticles: synthesis and applications

• Federica Compostella,
• Olimpia Pitirollo,
• Alessandro Silvestri and
• Laura Polito

Beilstein J. Org. Chem. 2017, 13, 1008–1021, doi:10.3762/bjoc.13.100

• commercial ELISA plates and anti-carbohydrate antibodies were detected in the nanomolar range both using purified anti-HIV human monoclonal antibodies or serum from immunized mice against S. pneumoniae. Detection of carbohydrate–influenza virus interactions The SERS methodology was extended to the

Total synthesis of a Streptococcus pneumoniae serotype 12F CPS repeating unit hexasaccharide

• Peter H. Seeberger,
• Claney L. Pereira and
• Subramanian Govindan

Beilstein J. Org. Chem. 2017, 13, 164–173, doi:10.3762/bjoc.13.19

• with 85% [17]. In order to improve current glycoconjugate vaccines additional serotypes such as 12F should be included in next-generation preparations [18]. Synthetic oligosaccharides are important tools for the identification of vaccine epitopes and have been the key to the creation of monoclonal

• antibodies that serve as tools for vaccine design [19] and for the detection of pathogenic bacteria such as Bacillus anthracis [20][21]. S. pneumoniae 12F CPS consists of hexasaccharide repeating units containing the [→4)-α-L-FucpNAc-(1→3)-β-D-GalpNAc-(1→4)-β-D-ManpNAcA-(1→] polysaccharide backbone with a

Rearrangements of organic peroxides and related processes

• Ivan A. Yaremenko,
• Vera A. Vil’,
• Dmitry V. Demchuk and
• Alexander O. Terent’ev

Beilstein J. Org. Chem. 2016, 12, 1647–1748, doi:10.3762/bjoc.12.162

Natural phenolic metabolites with anti-angiogenic properties – a review from the chemical point of view

• Qiu Sun,
• Jörg Heilmann and
• Burkhard König

Beilstein J. Org. Chem. 2015, 11, 249–264, doi:10.3762/bjoc.11.28

• , various therapies targeted at interfering with this process were investigated [6]. The favored clinical targets are the VEGF receptors, which have led to the development and approval of monoclonal antibodies against VEGF and VEGF receptor tyrosine kinase inhibitors [3]. However, the existing therapy

Human dendritic cell activation induced by a permannosylated dendron containing an antigenic GM₃-lactone mimetic

• Renato Ribeiro-Viana,
• Elena Bonechi,
• Javier Rojo,
• Clara Ballerini,
• Giuseppina Comito,
• Barbara Richichi and
• Cristina Nativi

Beilstein J. Org. Chem. 2014, 10, 1317–1324, doi:10.3762/bjoc.10.133

• incubation with LPS (1 µg/mL, Sigma–Aldrich), compound 5 and scaffold 7 (two doses, 50 and 10 µg/mL). DC phenotype The DC phenotype was analyzed by flow cytometry with a 4 color EpicsXL cytometer (Beckman–Coulter), equipped with Expo 32 software. Cell surface markers were labelled with monoclonal antibodies

Chemical modification allows phallotoxins and amatoxins to be used as tools in cell biology

• Jan Anderl,
• Hartmut Echner and
• Heinz Faulstich

Beilstein J. Org. Chem. 2012, 8, 2072–2084, doi:10.3762/bjoc.8.233

• oleic acid or polylysine and thus decrease the medium concentration necessary to achieve growth inhibition down to the nanomolar range. Amanitin as a drug bound to tumor monoclonal antibodies, has recently been described for the therapy of adenocarcinomas [34]. Coupling to methoxypolyethyleneglycol has

Synthesis of 4” manipulated Lewis X trisaccharide analogues

• Christopher J. Moore and
• France-Isabelle Auzanneau

Beilstein J. Org. Chem. 2012, 8, 1134–1143, doi:10.3762/bjoc.8.126

• -GlcNAcp), at the nonreducing end, and this antigenic determinant is also present at the surface of many normal cells and tissues, which include kidney tubules, gastrointestinal epithelial cells, and cells of the spleen and brain [7][8][9][10][11]. Indeed, anti-Lex monoclonal antibodies (e.g., FH3, SH1

• consider is an expected autoimmune response to the native Lex antigen. Fortunately an internal epitope displayed by dimLex was discovered when monoclonal antibodies (mAbs) FH4 and SH2, raised against dimLex, were isolated. Indeed, these mAbs were shown to bind to the dimLex and trimLex antigens but only

An easily accessible sulfated saccharide mimetic inhibits in vitro human tumor cell adhesion and angiogenesis of vascular endothelial cells

• Grazia Marano,
• Claas Gronewold,
• Martin Frank,
• Anette Merling,
• Christian Kliem,
• Sandra Sauer,
• Manfred Wiessler,
• Eva Frei and
• Reinhard Schwartz-Albiez

Beilstein J. Org. Chem. 2012, 8, 787–803, doi:10.3762/bjoc.8.89

• oligosaccharides interacting with the respective binding partners on neighboring cells. In this respect our results are reminiscent of a previous study in which we described the inhibition of endothelial networking by monoclonal antibodies against the histo blood group oligosaccarides Lewisy and H and further by